Appili Therapeutics Inc faces significant setbacks as its stock drops sharply.
Appili Therapeutics Inc (APLI.TO) is experiencing a substantial decline in its stock price, dropping by 33.33% today. This sharp downturn raises concerns among investors about the company's future prospects.
Investor takeaway: Investors should closely monitor Appili Therapeutics' developments, especially in light of recent contract terminations and financial results.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.99M
52W high
$0.04
52W low
$0.01
1W change
+50.00%
Beta
-0.21
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 900.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+900.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
207.3%
Annualized
90-Day Vol
222.9%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$0.02
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.02 | C$0.01 – C$0.03 |
| 60 trading days | C$0.02 | C$0.01 – C$0.04 |
| 90 trading days | C$0.02 | C$0.00 – C$0.05 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Appili Therapeutics Inc stock down 33.33% today
The stock's drop reflects investor concerns following the termination of a key contract and overall market sentiment.
Bull case
Despite today's decline, Appili has made progress in securing non-dilutive funding and advancing its commercial-stage programs. These efforts could lay the groundwork for a recovery.
Bear case
The termination of the VXV-01 program contract by NIAID raises serious questions about Appili's operational viability and future revenue streams. This uncertainty has contributed to today's stock drop.
Market Reaction
Advertisement
Appili's stock plummeted by 33.33% today, reflecting a negative market reaction to the company's recent announcement about the termination of its VXV-01 program contract with NIAID. This news has alarmed investors, who are now questioning the sustainability of Appili's business model.
Operational Concerns
The termination of the VXV-01 program is a significant blow to Appili's operational strategy. Investors are left wondering how this will impact the company's revenue potential moving forward. With a market cap of just CA$1,985,491, the pressure is mounting for Appili to prove its viability in the competitive biotech landscape.
Looking Ahead
As Appili Therapeutics navigates these challenges, investors should stay informed about upcoming developments, including any new funding opportunities and partnerships that may arise. The company's participation in events like the World Vaccine Congress could provide avenues for recovery, but the road ahead appears uncertain.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
